Protein profiling in daunorubicin-induced cardiomyopathy

General Physiology and Biophysics

Volumn 22, Issue 3, 2003, Pages 411-419

  Adamcová, Michaela ^a   Pelouch, V ^a   Gersl V ^a   Kaplanova J ^a   Mazurova Y ^a   Simunek T ^b   Klimtova I ^b   Hrdina, R ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Cardiomyopathy; Collagen; Daunorubicin; Dexrazoxane; Protein profile

Indexed keywords

COLLAGEN; CONTRACTILE PROTEIN; DAUNORUBICIN; RAZOXANE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CHINCHILLA; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXTRACTION; FUNCTIONAL ASSESSMENT; HEART EJECTION FRACTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION TIME; HEART PROTECTION; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; MALE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN ISOLATION; RABBIT; SAMPLING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; DAUNORUBICIN; HEART VENTRICLES; MALE; PROTEINS; RABBITS; RAZOXANE;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0346896472     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Adamcová M., Geršl V., Hrdina R., Mělka M., Mazurová Y., Vávrová J., Palička V., Kokštein Z. (1999): Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. J. Cancer Res. Clin. Oncol. 125, 268-274
2. Ferrans V. J. (1978): Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat. Rep. 62, 955-961
3. Ferrans V. J., Clark J. R., Zhang J., Yu Z. X., Herman E. H. (1997): Pathogenesis and prevention of doxorubicin cardiomyopathy. Tsitologiia, 39, 928-937
4. Geršl V., Hrdina R. (1994): Noninvasive polygraphic cardiac changes in daunorubicin-induced cardiomyopathy in rabbits. Sbor. věd. prací LFUK Hradec Králové 37, 49-55
5. Gulve E. A., Mabuchi K., Dice J. F. (1991): Regulation of myosin and overall protein-degradation in mouse C2 skeletal myotubes. J. Cell. Physiol. 147, 37-45
6. Hochster H., Liebes L., Wadler S., Oratz R., Wernz J. C., Meyers M., Greeen M., Blum R. H., Speyer J. L. (1992): Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J. Natl. Cancer Inst. 84, 1725-1730
7. Hrdina R., Geršl V., Klimtová V., Šimůnek T., Macháčková J., Adamcová M. (2000): Anthracycline-induced cardiotoxicity. Acta Medica (Hradec Králové) 43, 75-82
8. Kapelko V. (2001): Myocardial remodeling: The role of matrix metalloproteinases. Kardiologiya 41, 49-55
9. Laurent G., Jaffrezou J. P. (2001): Signaling pathways activated by daunorubicin. Blood 98, 913-924
10. Link G., Tirosh R., Pinson A., Hershko C. (1996): Role of iron in the potentiation of anthracycline cardiotoxicity: Identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J. Lab. Clin. Med. 127, 272-278
11. Lowry O. H., Rosenbrough H. J., Farr A. L., Randall R. J. (1951): Protein measurement with Folin phenol reagent. J. Biol. Chem. 913, 265-275
12. Muszynska A., Wolczynski S., Palka. J. (2001): The mechanism for anthracycline-induced inhibition of collagen biosynthesis. Eur. J. Pharmacol. 411, 17-25
13. Olson H. M., Young D. M., Prieur D. J. (1974): Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. Am. J. Pathol. 77, 439-454
14. Pelouch V., Milerová M., Oštádal B., Šamánek M., Hučín B. (1993): Protein profiling of human atrial and ventricular musculature: The effect of normoxaemia, and hypoxaemia in congenital heart diseases. Physiol. Res. 42, 235-242
15. Pelouch V., Milerová M., Oštádal B., Šamánek M., Hučín B. (1995): Differences between atrial and ventricular protein profiling in children with congenital heart disease. Mol. Cell. Biocliem. 147, 43-49
16. Shaper J., Elsasser A., Kostin S. (1999): The role of cell death in heart failure. Circ. Res. 85, 867-869
17. Weiss G., Loyevsky M., Gordeuk V. R. (1999): Dexrazoxane (ICRF-187). Gen. Pharmacol. 32, 155-158
18. Wexler L. H., Andrich M. P., Venzon D., Berg S. L., Weaver-McClure L., Chen C. C., Dilsizian V., Avila N., Jarosinski P., Balis F. M., Poplack D. G., Horowitz M. E. (1996): Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol. 14, 362-372
19. Woolf N. (199-2): Ischemia. and infarction. In: Oxford Textbook of Pathology (Eds. J. O'. D. McGee, P. G. Isaacson and N. A. Wright), pp. 525-530, Oxford University Press, Oxford-New York-Tokyo
20. Yang X. L., Wang A. H. J. (1999): Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol. Ther. 83, 181-215